Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving ...

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier ...

I rarely used the word “arthritis”, even when strangers asked why I limped or what was wrong with my knee, perhaps partly because of my resistance to the meaning of the name, as I ardently committed ...

Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar Therapeutics announced positive results from its mid-stage REZOLVE-AD study ...

Janus kinase (JAK) inhibitors are associated with decreased mortality and fewer serious adverse events among adults hospitalized with COVID-19.

So, the first JAK inhibitor came to market with the promise of getting oral efficacy, where previously it was injectable or infusible.

Some previous studies, including the ORAL Surveillance randomized trial, have shown moderately greater cancer risks with JAK inhibitors versus TNF inhibitors. But some other analyses of real-world ...

A major advantage of using JAK inhibitors in rheumatoid arthritis, or any other disease for that matter, is their ease of use.

Discover a study uncovering how JAK inhibitors protect against autoimmune diabetes triggered by cancer immunotherapy.

A novel dual Janus kinase/protein kinase inhibitor alleviates rheumatoid arthritis at higher doses without causing lipid or creatine kinase changes.

Use of Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) was associated with significantly higher rates of malignancies compared with biologic agents, data from a large German registry ...